Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)

OBJECTIVE: Advanced or recurrent endometrial cancer (EC) no longer amenable to surgery or radiotherapy is a life-threatening disease with limited therapeutic options left. Eighty percent of ECs express receptors for luteinizing hormone–releasing hormone (LHRH), which can be targeted by AEZS-108 (zop...

Descripción completa

Detalles Bibliográficos
Autores principales: Emons, Günter, Gorchev, Grigor, Harter, Philipp, Wimberger, Pauline, Stähle, Anne, Hanker, Lars, Hilpert, Felix, Beckmann, Matthias W., Dall, Peter, Gründker, Carsten, Sindermann, Herbert, Sehouli, Jalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Uterine Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921259/
https://www.ncbi.nlm.nih.gov/pubmed/24418927
http://dx.doi.org/10.1097/IGC.0000000000000044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921259/
https://www.ncbi.nlm.nih.gov/pubmed/24418927
http://dx.doi.org/10.1097/IGC.0000000000000044

Ejemplares similares